Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.38 USD | -1.65% | -14.44% | -9.28% |
Financials (USD)
Sales 2024 * | 515M | Sales 2025 * | 633M | Capitalization | 3.57B |
---|---|---|---|---|---|
Net income 2024 * | -533M | Net income 2025 * | -455M | EV / Sales 2024 * | 6.29 x |
Net cash position 2024 * | 334M | Net cash position 2025 * | 298M | EV / Sales 2025 * | 5.17 x |
P/E ratio 2024 * |
-6.71
x | P/E ratio 2025 * |
-8.39
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.88% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | -1.65% | ||
1 week | -14.44% | ||
Current month | -7.09% | ||
1 month | -6.89% | ||
3 months | +0.51% | ||
6 months | +36.72% | ||
Current year | -9.28% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | 0.00% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 43.38 | -1.65% | 768,249 |
24-04-17 | 44.11 | +4.25% | 908,192 |
24-04-16 | 42.31 | -1.31% | 886,829 |
24-04-15 | 42.87 | -8.79% | 1,727,295 |
24-04-12 | 47 | -7.30% | 786,724 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.28% | 3.57B | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-2.04% | 21.66B | |
-18.35% | 20.77B | |
-8.72% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- RARE Stock